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Abstract
Effective salvage options inducing high complete metabolic response (CMR) rates without significant toxicity are
needed for Hodgkin lymphoma (HL) patients failing induction treatment and who are candidate to autologous stem
cell transplantation (ASCT). Brentuximab vedotin (BV) and bendamustine are active monotherapies in the relapsed/
refractory setting and their combination (the BBV regimen) possibly enhances their activity. This single-arm multicenter
phase 2 study investigated the efficacy and safety of BBV as first salvage therapy in 40 patients with relapsed/refractory
HL. Thirty-eight patients were evaluable for efficacy: 30 (78.9%) had a CMR and 2 (5.3%) a partial response, leading to
an overall response rate (ORR) of 84.2%. The ORR in the primary refractory subset was 75.0%, among relapsed patients
it was 94.4%. Thirty-five patients could mobilize peripheral blood stem cells and 33 underwent ASCT. At a median
follow-up of 23 months, the estimated 3-year overall survival and progression-free survival are 88.1% and 67.3%.
During therapy, only 3 grade IV cases of neutropenia occurred and resolved within a week. No grade 4
extrahematologic toxicities were reported; skin reactions were however rather frequent (65%). These results suggest
that the BBV regimen exhibits promising efficacy and a manageable toxicity in a challenging subpopulation of HL
patients.
Introduction
The standard treatment for patients with classical
Hodgkin lymphoma (cHL) who are unresponsive to
upfront therapy or relapse after primary treatment consists
of salvage chemotherapy (aimed at harvesting autologous
stem cells from peripheral blood), followed by high-dose
chemotherapy and autologous stem cell transplantation
(ASCT). This latter phase has to be reserved only to those
patients who are able to tolerate a highly toxic con-
ditioning and a fairly prolonged myelosuppression.
Although this approach has yielded a long-term pro-
gression-free survival (PFS) in 50–60% of patients with
chemosensitive relapse1,2, outcomes remain poor in those
with primary chemorefractory disease, where long-term
survival rarely exceeds 15–17%3,4. Disease recurrence still
remains the principal cause of ASCT failure, and early
disease progression after transplant, i.e., within 6 months
from high-dose conditioning, emerges as a clear predictor
of unfavorable outcome4.
Under this light, optimization of the outcomes obtained
with high-dose regimens and ASCT still remains a
priority, which is required to offer the best chance of cure
for the largest fraction of patients with refractory and
relapsing disease5. In particular, any strategy aimed at
achieving a minimal disease status, and at specifically
obtaining a positron emission tomography (PET)-negative
status before ASCT without severe toxicity, would
represent a major advance in the overall management of
these patients6–9.
© The Author(s) 2019
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: P. L. Zinzani (pierluigi.zinzani@unibo.it)
1Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, Italy
2Hematology, Department of Oncology, University Hospital Città della Salute e
della Scienza, Torino, Italy



































Brentuximab vedotin (BV) potentially induces deep
responses when applied in the context of a first salvage
treatment before ASCT, even if as single agent10.
Importantly, BV displays a favorable toxicity profile,
without significant myelosuppression and with no cross-
resistance with most of the agents employed during
induction or high-dose conditionings. Moreover, BV
induces PET negativity in patients with advanced disease,
with clinical responses observed rather rapidly, i.e., within
the first 3–4 cycles in most responding subjects, allowing
the timely application of the transplantation proce-
dure11,12. Besides BV, the “freshly rediscovered” old
bendamustine has shown clinical activity in patients with
multitreated cHL13, and may also overcome the resistance
to previous BV treatment14. Both BV and bendamustine
can be administered on an outpatient basis, they are well
tolerated in terms of hematological adverse events (AEs)
and do not show overlapping toxicities11,13. For this rea-
son, there is a strong rationale to combine favorably these
two agents in order to exploit a synergistic effect with the
purpose of improving the remission rates observed with
either agent in the pre-ASCT setting. LaCasce and cow-
orkers presented some preliminary data on BV and
bendamustine combination in 2014 at the American
Society of Hematology Meeting: the phase 1 part of their
study was designed to determine the recommended dose
of bendamustine associated with BV. No dose-limiting
toxicities were observed during the trial, thus the authors
concluded that a standard dose of 1.8 mg/kg of BV could
be safely combined with 90mg/m2 of bendamustine15.
Here, we present the results of a phase 2 study evalu-
ating the efficacy and safety of the bendamustine plus BV
(BBV) regimen applied as first salvage strategy in patients
with cHL. The study protocol also contemplated the
enrolment of patients with relapsed or refractory CD30+
peripheral T-cell lymphomas in a separate cohort, for
which enrolment is still ongoing.
Patients and methods
Study oversight and patient population
This was a single-arm, open-label, multicenter, phase 2
clinical trial, aimed at evaluating the antitumor efficacy
and safety of the BBV combination as first salvage therapy
in patients with relapsed or refractory cHL. The study
involved seven Italian hematology centers adhering to the
Italian Lymphoma Foundation (Fondazione Italiana Lin-
fomi, FIL). The trial was conducted in accordance with
the Declaration of Helsinki and the study protocol was
approved by the Ethical Committee of the Coordinating
Center (Comitato Etico di Bologna) and by the Ethical
Committee of each participating site. Written informed
consent was obtained by patients before any study pro-
cedure. The trial was registered at www.clinicaltrials.gov,
NCT02499627, and given the EudraCT number
2014–005382–79.
Patients aged 18–60 years were eligible if affected by
histologically confirmed CD30+ cHL at first relapse or
with primary refractory disease (i.e., having received only
one previous line of treatment). Patients should have
never received either bendamustine or BV during induc-
tion and have never undergone ASCT. Fluorodeox-
yglucose avid and measurable disease documented by
both PET and computed tomography (CT) was required
for enrolment. Repeat biopsy was not considered man-
datory before entry into the trial, and rebiopsy was at the
discretion of the treating physician. Results of CD30
expression from the most recent postdiagnostic biopsy of
relapsed/refractory disease was obtained from pathology
reports of a tumor block (biopsy taken at diagnosis or
relapse) to enable study enrollment (per inclusion cri-
teria). Central review for CD30 expression (using BerH2
antibody) was performed on diagnostic histological
material. Diagnosis of HL was central reviewed by an
expert pathologist and his staff.
The applied salvage regimen consisted of intravenous
bendamustine, administered at a dose of 90mg/m2 on day 1
and 2, and BV, given at the total dose of 1.8mg/kg on day 1
of each 21-days-based cycle. Drug premedication was
mandatory and included corticosteroids and antihistamines.
Up to 6 cycles of the combination regimen were allowed
(Fig. 1). All patients achieving at least a disease stability
could be considered eligible to peripheral blood stem cell
(PBSC) mobilization (performed with granulocyte colony-
stimulating factor [G-CSF] and plerixafor, if required) and
could proceed to ASCT at any time beyond cycle 4.
Patients in response were allowed to undergo ASCT after
2 cycles, if they experienced any toxicity that would pre-
vent a safe delivery of subsequent cycles, according to
physician’s judgement. Treatment was concluded in case
of disease progression or development of unacceptable
toxicity, whichever came first.
Study assessments
The anticancer activity of this regimen was assessed
according to the Lugano Classification at the end of the
combination treatment16. ASCT, if performed, was not
intended as part of the study protocol. Dedicated CT scan
of neck, chest, abdomen, and pelvis (with and without
contrast) was performed at baseline, after cycles 2 and 4,
and within 30 ± 7 days after cycle 6 or early study with-
drawal. PET scan was also repeated after cycle 3 and
within 30 ± 7 days after cycle 6 or early study dis-
continuation (Fig. 1). For patients proceeding to ASCT
after cycle 2 or 4, a pre-ASCT PET scan had to be per-
formed before conditioning, provided this had not been
done earlier than 6 ± 1 weeks. PET scans were scored
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according to the Deauville five-point scale17 and were
centrally reviewed.
Study endpoints and statistics
The primary endpoint of the study was the overall
response rate (ORR) and the complete metabolic response
(CMR) rate to the combination regimen. Secondary
endpoints were represented by PFS, overall survival (OS)
and disease-free survival (DFS) at 1 year. PFS and OS were
calculated for all patients since the entry onto study; DFS
was determined in all CMR patients from the moment in
which a response was documented to the first determi-
nation of relapse, progression, or death from any cause.
All patients receiving at least 2 cycles of the treatment and
undergoing disease status reassessment by both CT and
PET scan constituted the efficacy-evaluable population.
Sample size estimation was performed by Fleming's
single-stage procedure. Defined p0 as the proportion of
response below which the treatment does not warrant
further investigations and pa as the proportion of
responses beyond which a phase 3 trial should be carried
out, we set p0= 0.5 and pa= 0.8. The number of patients
required, given a type I error (alpha) at 0.05 one sided and
a power of 1-beta= 80%, is 36 and the number of suc-
cesses 28. Taking into account a drop out of 10%, the
number of patients was set at 40.
Safety assessment was performed in all patients receiv-
ing at least one dose of the combined treatment. The
severity of AEs was graded according to the National
Cancer Institute Common Terminology Criteria for AEs,
version 4.03. Additional analyses were addressed to
establish the feasibility of PBSC collection, in terms of
percentage of success and amount of PBSC harvested.
Demographics and patients’ characteristics were sum-
marized by descriptive statistics (median and range),
and survival functions were estimated by using the
Kaplan–Meier method. Statistical analyses were per-
formed with Stata 11 (StataCorp LP, TX).
Results
Forty patients with refractory (N= 20, 50%) or relapsed
(N= 20, 50%) cHL were enrolled in the study between
January 2016 and December 2017, at a median time of
7 months (range: 5–67), since disease diagnosis. Median
age at the beginning of the salvage treatment was 38
(range: 20–59) years. Eight patients displayed extranodal
involvement, including bone (three patients), lung (three
patients), liver (one patient), and liver and lung (one
patient). Induction treatment consisted of doxorubicin,
bleomycin, vinblastine, and dacarbazine in all cases. In
one patient, doxorubicin was administered as a liposomal
formulation. The median number of BBV cycles
received was 4.
Response to treatment and stem cell mobilization
Thirty-eight patients were assessable for disease
response at the end of the BBV regimen. Two patients, in
fact, displayed disease progression before the first CT scan
reassessment. An objective response was observed in 32 of
the evaluable patients (84.2%), with 30 of them obtaining a
CMR (78.9%) and 2 a partial response (PR; 5.3%). A
detailed breakdown of Deauville scores along with the
associated clinical response is given in Table 1. The ORR
in the primary refractory subset was 75.0% (with a CMR
rate of 65.0%), while among relapsed patients it reached
94.4% (all patients in CMR). If the whole patient popu-
lation intended to receive the treatment were considered
(all the 40 patients enrolled), the ORR would be 80%, with
a CMR rate of 75% and a PR rate of 5%.
Thirty-five (92.1%) patients underwent PBSC mobiliza-
tion. Plerixafor was applied, together with G-CSF, in 12
patients (34.3%). Mobilization and harvest were successful
in all cases, with a median CD34+ cells/kg yield of 3.2 ×
106. Thirty-three patients (86.8%) proceeded to ASCT, all
of them obtaining a complete response (CR) after this
procedure. ASCT was performed after a median of 4
(range: 2–6) cycles. The two patients who did not proceed
to ASCT, although being able to mobilize PBSC, obtained
a PR and a disease stability after BBV, but showed a disease
progression immediately before the conditioning regimen
was started. Patient disposition is summarized in Fig. 2.
Survival analysis
With a median follow-up of 23 months from enrolment
into the trial, the OS rates at 1 and 3 years are 100% and
88.1%, respectively. Two patients died during the post-
treatment follow-up at 12.6 and 28.6 months, respectively,
in both cases as a result of disease progression. The PFS
rates are 78.9% and 67.3%, and the DFS rates are 86.1%
and 81.9% at 1 and 3 years, respectively (Figs. 3 and 4).
Fig. 1 Treatment plan and timing of CT and PET scan
assessments. (*) Patients in response were allowed to undergo ASCT
after 2 cycles in case of severe toxicity (see text for details). IR, infusion
reaction; ASCT, autologous stem cell transplantation; PBSC, peripheral
blood stem cells; and G-CSF, granulocyte colony-stimulating factor.
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Five patients in CMR relapsed during follow-up at 7.5, 7.7,
10.9, 11.9, and 15.1 months since the obtainment of
the CR.
Toxicity
Table 2 summarizes the incidence and the severity of
any reported AE. Overall, 41 hematological AEs of any
grade occurred during the treatment with BBV, involving
14 patients (35.0%). We observed 13 episodes of neu-
tropenia, 12 of leucopenia, 8 of anemia, and 7 of throm-
bocytopenia. Febrile neutropenia was reported in one
patient: this led to hospitalization, but it rapidly resolved
concomitantly with granulocyte recovery. Thirty-eight
episodes (92.7%) were judged related to the administered
regimen. Only 3 grade IV AEs occurred: they all consisted
of transient neutropenia, which resolved within a week
and without further complications.
In terms of extrahematological toxicity, 166 AEs of any
grade occurred during the course of BBV, overall invol-
ving 37 patients (92.5%). Among these AEs, 135 (81.3%)
were considered therapy related. Most of the AEs were
mild (grade I and II) and grade III AEs were observed only
in ten cases. No grade IV extrahematological toxicities
have been reported. The most frequent AE was repre-
sented by skin reactions (reported with the synonyms:
skin reaction, erythema, popular eruption, rash, maculo-
papular rash, and hives), which consisted of 46 episodes,
involving 26 patients overall. This AE was judged certainly
correlated with the study regimen in seven cases (15.2%),
possibly or probably related in 33 cases (71.7%), probably
unrelated in three instances (6.5%), whereas it was
attributed to other medications in three cases (6.5%). The
median duration of skin-related toxicity was 6 (range:
1–96) days; in 19 cases, the duration was shorter than or
equal to 3 days, thus indicating a close relationship with
the timing of administration of the study drug combina-
tion. Seventeen patients experienced fever (26 episodes
overall), whose median duration was 3 (range: 1–21) days.
In 19 cases, the duration was shorter than or equal to
3 days, which encompassed the 3-days duration of
administration of the BBV regimen. Infusion-related
reactions (IRR) occurred in five patients (six episodes):
notably, they manifested with respiratory failure and
dyspnea in one case each. The incidence of BV-induced
peripheral neuropathy was indeed rather low: it mani-
fested with grade 1 paresthesias in three patients (1.8%),
and it was reversible in all cases.
Seven patients (17.5%) permanently discontinued BBV
due to an AE, in six cases because of grade III skin
reaction and in one case as a consequence of grade III
neutropenia.
Long-term toxic effects are at present unknown: we
report no secondary malignancies so far.
Discussion
Ideally, a first salvage regimen should allow: (i) an
effective disease control, which needs to translate into the
chance of reinduce high CR rates; (ii) a proper
Fig. 2 Patient disposition. CMR, complete metabolic response; PR,
partial response; SD, stable disease; PD, disease progression; PBSC,
peripheral blood stem cells; ASCT, autologous stem cell transplantation.
Table 1 Clinical responses according to the Deauville
five-point scale.
Patients (N= 38) %
Complete metabolic response
Deauville 1 5 13.1
Deauville 2 19 50.0
Deauville 3 6 15.8
Partial response
Deauville 4 2 5.3
No metabolic response/stable disease
Deauville 4 1 2.6
Deauville 5 1 2.6
Progressive disease
Deauville 4 1 2.6
Deauville 5 3 7.9
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mobilization of PBSC without the use of further che-
motherapy in patients for whom ASCT is an option; (iii) a
long duration of response in those who are not candidate
for a high-dose consolidation, after having obtained an
adequate response; and (iv) a good toxicity profile, most of
all without myelotoxic events and hopefully avoiding
prolonged peripheral cytopenias.
The effective combination of bendamustine and BV in
the first salvage setting is supported by a relevant rate of
objective responses observed in patients with relapsed or
refractory cHL, along with a significant proportion of
CMR (84.2% and 78.9%, respectively), stringently con-
firmed by the application of the Deauville score (Deauville
1–3). The BBV regimen is also a safe alternative to con-
ventional chemotherapy, as it displays limited myelo-
toxicity and does not impair a subsequent mobilization of
PBSC: this is confirmed by the fact that 92.1% of patients
could successfully accomplish harvest with a rate of suc-
cess of 100%. Besides that, however, we cannot exclude a
potential toxicity of this regimen on the stem cell itself, as
demonstrated by the fact that at least a third of patients
required plerixafor to obtain an effective stem cell
mobilization in peripheral blood.
Notably, the BBV combination has activity in primary
refractory patients, suggesting its potential role in a disease
that lacks a proper response to conventional cytostatic
drugs. IRR represent the most relevant extrahematological
toxicity: albeit observed frequently, they were generally
mild and transient, due to a mandatory premedication
with steroids and antihistamines, and they were the cause
of treatment interruption just in a few cases.
Similar results have been obtained in an earlier report
by LaCasce et al. for the same treatment context and in a
population with overlapping clinical characteristics15,18: a
complete response (CR) was observed in 73.6% of
patients, with an ORR of 92.5% (according to the 2007
Revised Response Criteria for Malignant Lymphoma19),
including 85.7% among those with primary refractory
cHL. PBSC collection was not impaired either, as most of
patients could harvest an adequate amount of CD34+
cells at first attempt following G-CSF alone or cyclo-
phosphamide priming and plerixafor, obtaining a median
yield of 4.2 × 106/kg. About 73% of the patients enrolled in
this trial received a subsequent ASCT after a median of
BBV cycles, in comparison to 88% of the patients enrolled
in our study, who did not proceed to ASCT only because of
disease progression. Similarly to our trial, IRR occurred in
56.4% of patients as a consequence of the combination
therapy, therefore requiring a mandatory premedication to
be introduced while the study was ongoing: this decreased
the severity of IRR, although not clearly reducing their
incidence. Importantly, an optional post-ASCT main-
tenance phase with single-agent BV was planned in the
trial by LaCasce et al., which was not part of the treatment
in our study: this may have impacted on the survival out-
comes of patients not receiving an ASCT consolidation19.
High remission rates and promising long-term survival
results have been equally shown with the same combina-
tion in patients failing more than one previous line of
therapy, including some heavily pretreated patients20,21.
BV has also been combined with conventional che-
motherapy schedules, such as ICE (ifosfamide, cytarabine,
Fig. 3 OS and PFS curves plotted for all the patients enrolled in the study.
Fig. 4 DFS curve for all the patients who obtained a complete
metabolic response.
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Table 2 AEs of any grade.
Toxicity Patients involved, N Events, N Overall frequency (%) Grade 1, N Grade 2, N Grade 3, N Grade 4, N
Hematological toxicity 14 41 100 16 7 15 3
Neutropenia 8 13 31.7 2 8 3
Leukopenia 6 12 29.3 2 4 6
Anemia 8 8 19.5 7 1
Thrombocytopenia 5 7 17.1 7
Febrile neutropenia 1 1 2.4 1
Extrahematological toxicity 37 166 100 87 69 10 0
Skin reaction 26 46 27.7 19 21 6
Fever 17 26 15.7 18 7 1
Nausea 14 24 14.5 16 8
CMV infection/reactivation 4 9 5.4 1 8
Diarrhea 4 8 4.8 4 4
Infusion-related reaction 5 6 3.6 1 5
Vomiting 4 6 3.6 4 2
ALT increase 3 5 3.0 4 1
Flu-like syndrome 4 4 2.4 1 3
Muscle/joint pain 4 4 2.4 4
Paresthesia 3 3 1.8 3
AST increase 2 2 1.2 2
Dyspnea 2 2 1.2 1 1
Fatigue 2 2 1.2 2
Gamma-GT increase 2 2 1.2 1 1
Pruritus 2 2 1.2 1 1
Abdominal pain 1 1 0.6 1
Alkaline phosphatase
increase
1 1 0.6 1
Bronchial infection 1 1 0.6 1
Candidosis 1 1 0.6 1
Catheter infection 1 1 0.6 1
Cold 1 1 0.6 1
Constipation 1 1 0.6 1
Heartburn 1 1 0.6 1
Palpitations 1 1 0.6 1
Pharyngitis 1 1 0.6 1
Phlebitis 1 1 0.6 1
Respiratory failure 1 1 0.6 1
Sinus tachycardia 1 1 0.6 1
Vaginal spotting 1 1 0.6 1
Viral gastroenteritis 1 1 0.6 1
CMV cytomegalovirus, ALT alanine transaminase, AST aspartic transaminase, gamma-GT gamma glutamyl-transpeptidase
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and etoposide), DHAP (dexamethasone, cytarabine, and
cisplatin), and ESHAP (etoposide, prednisolone, cytarabine,
and cisplatin): according to preliminary results, all these
combinations proved effective in the first salvage setting,
with CR rates ranging from 69% to 100%, again without
hampering PBSC mobilization and harvesting22–24. Very
recently, the first chemo-free combination, consisting of
BV and the antiprogrammed death 1 (PD1) blocker nivo-
lumab, has been reported in patients with cHL failing
induction: the ORR was 82% and the CMR rate 61%, higher
than those observed with either agent given alone, and
quite similar to what was obtained with BV and bend-
amustine or ifosfamide/cisplatin-containing regimens25.
This experience is notable, as it further strengthens the
possible role of BV in first salvage settings and provides a
sound rationale for chemo-free approaches in relapsed and
refractory cHL patients.
Our results, along with previously reported ones, con-
firm that BV combinations can be profitably exploited in a
first salvage setting, where they permit a timely and
effective application of the ASCT phase, when indi-
cated15,18,22–24,26. Most of all, in respect of the obtainment
of a CMR, which is indeed one of the most predictors of
post-ASCT survival6,9. These results favorably compare to
what has been obtained with the bendamustine, gemci-
tabine, and vinorelbine (BeGeV) regimen, which yielded
an ORR of 83% and a CR rate of 73%, with an incidence of
grade 3–4 neutropenia, and thrombocytopenia of 14%
each and febrile neutropenia of 12%27. These results score
higher than what was described for ifosfamide/cisplatin-
containing regimens and should represent a point of
reference for any newer regimen that contemplates agents
like BV or anti-PD1 blockers.
BBV and BV-containing first salvage regimes are pro-
posed as a valid alternative to conventional chemother-
apy. These regimes certainly represent an attempt to
incorporate targeted agents—concomitantly reducing the
chemotherapy load—in the treatment of high-risk
patients with cHL, and their role appears relevant in
those patients who inadequately respond to standard
induction. The lack of significant myelotoxicity and the
reduced morbidity correlated with prolonged or pro-
found cytopenias could make a regimen like BBV
exploitable also in patients, who require an effective
salvage although not being candidate to ASCT: this may
be inferred by any of the reported experiences, despite
none of the studies was specifically addressed to an
ASCT-ineligible population.
In conclusion, data suggest that the synergism of
bendamustine and BV exhibits promising results in a
challenging subpopulation of cHL patients. In the era of
new drugs for the treatment of cHL, whether BV-
containing regimens can replace conventional che-
motherapy deserves further investigation.
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